Evidence map›Paper›PMID 33800282›Full record

ReviewCancers2021

Expedition into Exosome Biology: A Perspective of Progress from Discovery to Therapeutic Development.

Arif Tasleem Jan, Safikur Rahman, Raied Badierah, Eun Ju Lee, Ehab H Mattar, Elrashdy M Redwan, Inho Choi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arif Tasleem JanSchool of Biosciences and Biotechnology, Baba Ghulam Shah Badshah University, Rajouri 185234, India.ORCID 0000-0002-3607-543X
Safikur RahmanDepartment of Botany, MS College, BR Ambedkar Bihar University, Muzaffarpur, Bihar 842001, India.
Raied BadierahBiological Sciences Department, Faculty of Science, and Laboratory University Hospital, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.
Eun Ju LeeDepartment of Medical Biotechnology and Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea.
Ehab H MattarBiological Sciences Department, Faculty of Science, and Laboratory University Hospital, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-8396-4547
Elrashdy M RedwanBiological Sciences Department, Faculty of Science, and Laboratory University Hospital, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-8246-0075
Inho ChoiDepartment of Medical Biotechnology and Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea.

Funding

National Research Foundation of Korea 2020R1A6A1A03044512; 2018R1A2B6001020
6 · The paper itself

Abstract

Exosomes are membrane-enclosed distinct cellular entities of endocytic origin that shuttle proteins and RNA molecules intercellularly for communication purposes. Their surface is embossed by a huge variety of proteins, some of which are used as diagnostic markers. Exosomes are being explored for potential drug delivery, although their therapeutic utilities are impeded by gaps in knowledge regarding their formation and function under physiological condition and by lack of methods capable of shedding light on intraluminal vesicle release at the target site. Nonetheless, exosomes offer a promising means of developing systems that enable the specific delivery of therapeutics in diseases like cancer. This review summarizes information on donor cell types, cargoes, cargo loading, routes of administration, and the engineering of exosomal surfaces for specific peptides that increase target specificity and as such, therapeutic delivery.

Indexed as

antigencancerexosomesimmune responsetherapeutics

Identifiers

PMID33800282
PMCPMC7962655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.